| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks | Director
3 companies
Hecht Beth is a See Remarks at XERS, with reported holdings spanning 3 companies. Recent filings cover 0 purchases and 14 sales. Those positions are worth an estimated $10.5M at current prices.
Our model assigns Hecht Beth a below-average insider score of 46/100, based on 6 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -0.2%.
Hecht Beth's largest disclosed position is in XERS as See Remarks, worth about $10.5M. The recent filings there lean toward selling, a net 240,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2025 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Sell10b5-1 | 16,667 | $7.01 | $116,780.67 | -1.2% | -13.5% | - | |
| Nov 11, 2025 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Sell10b5-1 | 16,667 | $7.40 | $123,295.80 | -1.2% | -6.5% | - | |
| Mar 20, 2025 | XERS Xeris Biopharma Holdings, Inc. | See Remarks | Sell | 40,000 | $5.43 | $217,244.00 | -2.9% | -15.7% | +0.2% |